Postow, Michael

Selected publications

Another victory for immune checkpoint blockade in melanoma: Adjuvant ipilimumab over interferon. Journal of Clinical Oncology. 2020 Editorial Article GET IT
Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab. Melanoma Research. 2020 Academic Article GET IT
Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature. Oncologist. 2020 Review GET IT
Intravitreous Cutaneous Metastatic Melanoma in the Era of Checkpoint Inhibition: Unmasking and Masquerading. Ophthalmology. 2020 Academic Article GET IT
Treatment Outcomes of Immune-Related Cutaneous Adverse Events. Journal of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 6
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. The Lancet Oncology. 2019 Review GET IT
Times cited: 7
Rational design of anti-GITR-based combination immunotherapy. Nature Medicine. 2019 Academic Article GET IT
Times cited: 15
Evaluation of the Response of Unresectable Primary Cutaneous Melanoma to Immunotherapy Visualized with Reflectance Confocal Microscopy: A Report of 2 Cases. JAMA Dermatology. 2019 Academic Article GET IT
Times cited: 3
Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience. Oncologist. 2019 Information Resource GET IT
Times cited: 5
Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. Journal of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 3
Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement. Journal for ImmunoTherapy of Cancer. 2018 Academic Article GET IT
Times cited: 3
Bigger Is Not Always Better: Tumor Size and Prognosis in Advanced Melanoma. Clinical Cancer Research. 2018 Academic Article GET IT
Times cited: 4
Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab. Journal of Clinical Endocrinology and Metabolism. 2018 Academic Article GET IT
Times cited: 16
Combined nivolumab and ipilimumab in melanoma metastatic to the brain. New England Journal of Medicine. 2018 Academic Article GET IT
Times cited: 180
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy). Journal of Translational Medicine. 2018 Academic Article GET IT
Times cited: 2
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Science Translational Medicine. 2018 Academic Article GET IT
Times cited: 56
The brim of uncertainty in adjuvant treatment of melanoma. The Lancet Oncology. 2018 Academic Article GET IT
Reply to M. Horiguchi et al. Journal of Clinical Oncology. 2018 Academic Article GET IT
Sequential, multiple assignment, randomized trial designs in immuno-oncology research. Clinical Cancer Research. 2018 Academic Article GET IT
Times cited: 1
Participatory implementation science to increase the impact of evidence-based cancer prevention and control. Cancer Causes and Control. 2018 Academic Article GET IT
Times cited: 7
Nivolumab plus ipilimumab in patients with advanced melanoma: Updated survival, response, and safety data in a phase i dose-escalation study. Journal of Clinical Oncology. 2018 Article GET IT
Times cited: 56
High response rate to PD-1 blockade in desmoplastic melanomas. Nature. 2018 Academic Article GET IT
Times cited: 70
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. New England Journal of Medicine. 2018 Review GET IT
Times cited: 539
Immune-related Adverse Events in Cancer Patients. Academic Emergency Medicine. 2018 Academic Article GET IT
Times cited: 3
LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. Cell. 2018 Academic Article GET IT
Times cited: 46
Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma. JAMA oncology. 2018 Article GET IT
Times cited: 38
Non-conventional Inhibitory CD4⁺Foxp3⁻PD-1^hiT Cells as a Biomarker of Immune Checkpoint Blockade Activity. Cancer Cell. 2018 Academic Article GET IT
Times cited: 24
Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. Cancer Medicine. 2018 Academic Article GET IT
Times cited: 20
Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: A pooled analysis of randomized phase II and III trials. Journal of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 123
Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016. Journal of Translational Medicine. 2017 Academic Article GET IT
Times cited: 8
The need for a network to establish and validate predictive biomarkers in cancer immunotherapy. Journal of Translational Medicine. 2017 Editorial Article GET IT
Times cited: 11
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine. 2017 Academic Article GET IT
Times cited: 933
Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial. OncoImmunology. 2017 Article GET IT
Times cited: 2
Health-related quality of life results from the phase III CheckMate 067 study. European Journal of Cancer. 2017 Academic Article GET IT
Times cited: 23
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treatment Reviews. 2017 Review GET IT
Times cited: 82
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017 Academic Article GET IT
Times cited: 374
Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: The role of checkpoint inhibition in the bone. Journal for ImmunoTherapy of Cancer. 2017 Academic Article GET IT
Times cited: 1
Elevated Blood Neutrophil-to-Lymphocyte Ratio: A Readily Available Biomarker Associated with Death due to Disease in High Risk Nonmetastatic Melanoma. Annals of Surgical Oncology. 2017 Academic Article GET IT
Times cited: 16
Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment. EBioMedicine. 2017 Academic Article GET IT
Times cited: 37
Patient perspectives on ipilimumab across the melanoma treatment trajectory. Supportive Care in Cancer. 2017 Academic Article GET IT
Times cited: 3
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. European Journal of Cancer. 2017 Academic Article GET IT
Times cited: 19
Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. Journal of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 268
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. Journal for ImmunoTherapy of Cancer. 2017 Academic Article GET IT
Times cited: 42
Reaffirming and clarifying the American Society of Clinical Oncology's policy statement on the critical role of phase i trials in cancer research and treatment. Journal of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 10
A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma. British Journal of Dermatology. 2017 Academic Article GET IT
Times cited: 14
A step forward for patients with NRAS-mutant melanoma. The Lancet Oncology. 2017 Comment GET IT
Times cited: 1
Better use of immune checkpoint inhibition: Treating higher risk patients and examining neurologic toxicity. Annals of Oncology. 2017 Academic Article GET IT
Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy. Differences from Central Serous Chorioretinopathy. Ophthalmology. 2017 Academic Article GET IT
Times cited: 23
Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. Journal of immunotherapy (Hagerstown, Md. : 1997). 2017 Academic Article GET IT
Times cited: 6
Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation. Oncotarget. 2017 Academic Article GET IT
Times cited: 4
Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. British Journal of Dermatology. 2017 Academic Article GET IT
Times cited: 33
Radiotherapy and Immune Checkpoint Blockade for Melanoma: A Promising Combinatorial Strategy in Need of Further Investigation. Cancer Journal. 2017 Review GET IT
Times cited: 12
Reduced-dose ipilimumab with standard-dose pembrolizumab: Is less more?. The Lancet Oncology. 2017 Comment GET IT
Times cited: 2
Thinking critically about classifying adverse events: Incidence of pancreatitis in patients treated with nivolumab + ipilimumab. Journal of the National Cancer Institute. 2017 Academic Article GET IT
Times cited: 24
Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clinical Cancer Research. 2016 Academic Article GET IT
Times cited: 198
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016 Academic Article GET IT
Times cited: 112
Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. Journal of Translational Medicine. 2016 Article GET IT
Times cited: 13
The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer. 2016 Academic Article GET IT
Times cited: 76
An open-label, dose-escalation phase I study of anti-TYRP1 monoclonal antibody IMC-20D7S for patients with relapsed or refractory melanoma. Clinical Cancer Research. 2016 Academic Article GET IT
Times cited: 5
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. The Lancet Oncology. 2016 Academic Article GET IT
Times cited: 400
Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell and Melanoma Research. 2016 Review GET IT
Times cited: 38
Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma. Melanoma Research. 2016 Academic Article GET IT
Times cited: 10
Increases in absolute lymphocytes and circulating CD4⁺ and CD8⁺ T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab. Clinical Cancer Research. 2016 Academic Article GET IT
Times cited: 65
Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist. 2016 Review GET IT
Times cited: 112
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA oncology. 2016 Review GET IT
Times cited: 246
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. European Journal of Cancer. 2016 Academic Article GET IT
Times cited: 23
Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment. Experimental Dermatology. 2016 Information Resource GET IT
Times cited: 7
Prognosis of mucosal, uveal, acral, nonacral cutaneous, and unknown primary melanoma from the time of first metastasis. Oncologist. 2016 Academic Article GET IT
Times cited: 41
corrigenda to Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies [Ann Oncol 26 (2015) 2375-2391, doi:10.1093/annonc/mdv383]. Annals of Oncology. 2016 Academic Article GET IT
Times cited: 63
Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clinical Cancer Research. 2016 Academic Article GET IT
Times cited: 208
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. European Journal of Cancer. 2016 Review GET IT
Times cited: 123
Immune checkpoint inhibitor combinations in solid tumors: Opportunities and challenges. Immunotherapy. 2016 Review GET IT
Times cited: 48
Targeting T Cell Co-receptors for Cancer Therapy. Immunity. 2016 Review GET IT
Times cited: 208
Reply to N. Lowy et al and to J. Dhanda et al. Journal of Clinical Oncology. 2016 Academic Article GET IT
Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunology Research. 2016 Academic Article GET IT
Times cited: 119
Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition. Current Oncology Reports. 2016 Review GET IT
Times cited: 26
Reply to A. Indini et al. Journal of Clinical Oncology. 2016 Information Resource GET IT
A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma. Melanoma Research. 2016 Academic Article GET IT
Times cited: 4
Checkpoint blockade for the treatment of advanced melanoma. Cancer treatment and research. 2016 Review GET IT
Times cited: 25
Editorial. Clinical Skin Cancer. 2016 Editorial Article GET IT
Head and neck cutaneous melanoma. 2016 Chapter GET IT
Irradiation and immunotherapy: From concept to the clinic. Cancer. 2016 Review GET IT
Times cited: 37
Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response. Head and Neck. 2016 Academic Article GET IT
Times cited: 27
Primary mucosal melanomas of the head and neck. 2016 Chapter GET IT
The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clinical Infectious Diseases. 2016 Academic Article GET IT
Times cited: 51
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Annals of Oncology. 2015 Review GET IT
Times cited: 508
Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology statement. Journal of Clinical Oncology. 2015 Review GET IT
Times cited: 148
Safety of infusing ipilimumab over 30 minutes. Journal of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 12
Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature. 2015 Academic Article GET IT
Times cited: 96
Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. Journal of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 378
Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma. Journal for ImmunoTherapy of Cancer. 2015 Academic Article GET IT
Times cited: 65
Immune checkpoint blockade in cancer therapy. Journal of Clinical Oncology. 2015 Review GET IT
Times cited: 1072
Immune checkpoint modulation: Rational design of combination strategies. Pharmacology and Therapeutics. 2015 Review GET IT
Times cited: 62
Anticancer immunotherapy by CTLA-4 blockade: Obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Research. 2015 Academic Article GET IT
Times cited: 79
American society of clinical oncology policy statement update: The critical role of phase I trials in cancer research and treatment. Journal of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 51
Anticancer immunotherapy by CTLA-4 blockade: Obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Research. 2015 Article GET IT
Times cited: 21
Combined nivolumab and ipilimumab or monotherapy in untreated Melanoma. New England Journal of Medicine. 2015 Academic Article GET IT
Times cited: 3139
Immune-priming of the tumor microenvironment by radiotherapy: Rationale for combination with immunotherapy to improve anticancer efficacy. American Journal of Clinical Oncology: Cancer Clinical Trials. 2015 Review GET IT
Times cited: 51
Liver resection and ablation for metastatic melanoma: A single center experience. Journal of Surgical Oncology. 2015 Academic Article GET IT
Times cited: 11
Managing immune checkpoint-blocking antibody side effects. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting. 2015 Review GET IT
Times cited: 211
Melanoma and non-melanoma skin cancers in hairy cell leukaemia: A Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center. British Journal of Haematology. 2015 Academic Article GET IT
Times cited: 6
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. New England Journal of Medicine. 2015 Academic Article GET IT
Times cited: 1519
On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Science Translational Medicine. 2015 Review GET IT
Times cited: 86
Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: Safety profile and efficacy of combined treatment. International Journal of Radiation Oncology Biology Physics. 2015 Academic Article GET IT
Times cited: 185
Immunologic checkpoints in cancer therapy: Focus on the programmed death-1 (PD-1) receptor pathway. Pharmacogenomics and Personalized Medicine. 2014 Review GET IT
Times cited: 71
CTLA-4 antibodies: new directions, new combinations. ONCOLOGY. 2014 Review GET IT
Times cited: 18
Ipilimumab in patients with melanoma and autoimmune disease. Journal for ImmunoTherapy of Cancer. 2014 Academic Article GET IT
Times cited: 62
Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. Cancer Immunology Research. 2014 Academic Article GET IT
Times cited: 71
Opportunistic infections in patients treated with immunotherapy for cancer. Journal for ImmunoTherapy of Cancer. 2014 Academic Article GET IT
Times cited: 54
Combinations of radiation therapy and immunotherapy for melanoma: A review of clinical outcomes. International Journal of Radiation Oncology Biology Physics. 2014 Review GET IT
Times cited: 92
Checkpoint blocking antibodies in cancer immunotherapy. FEBS Letters. 2014 Review GET IT
Times cited: 165
Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma. Methods in Molecular Biology. 2014 Academic Article GET IT
Times cited: 7
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. The Lancet. 2014 Academic Article GET IT
Times cited: 1093
Current options and future directions in the systemic treatment of metastatic melanoma. Journal of Community and Supportive Oncology. 2014 Article GET IT
Times cited: 3
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: A comprehensive retrospective review from a single institution. Endocrine-Related Cancer. 2014 Review GET IT
Times cited: 199
Genetic basis for clinical response to CTLA-4 blockade in melanoma. New England Journal of Medicine. 2014 Academic Article GET IT
Times cited: 1938
Immune modulation in cancer with antibodies. Annual Review of Medicine. 2014 Review GET IT
Times cited: 265
Clinical activity of ipilimumab for metastatic uveal melanoma: A retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer. 2013 Academic Article GET IT
Times cited: 113
Checkpoint modulation in melanoma: An update on ipilimumab and future directions. Current Oncology Reports. 2013 Review GET IT
Times cited: 17
Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunology Research. 2013 Review GET IT
Times cited: 97
Nivolumab plus Ipilimumab in advanced melanoma. New England Journal of Medicine. 2013 Academic Article GET IT
Times cited: 2557
Ipilimumab for patients with advanced mucosal melanoma. Oncologist. 2013 Academic Article GET IT
Times cited: 89
Antibodies to Stimulate Host Immunity: Lessons from Ipilimumab. 2013 Chapter GET IT
Times cited: 2
Immunomodulatory therapy for melanoma: Ipilimumab and beyond. Clinics in Dermatology. 2013 Review GET IT
Times cited: 36
Mucosal melanoma: Pathogenesis, clinical behavior, and management. Current Oncology Reports. 2012 Review GET IT
Times cited: 56
A man with Klinefelter's syndrome and new abdominal distension: A discussion of evaluation and management. Journal of Gastrointestinal Cancer. 2012 Academic Article GET IT
Times cited: 1
The authors reply. New England Journal of Medicine. 2012 Article GET IT
Times cited: 5
The antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime?. Clinical Cancer Research. 2012 Comment GET IT
Times cited: 25
Immunologic correlates of the abscopal effect in a patient with melanoma. New England Journal of Medicine. 2012 Academic Article GET IT
Times cited: 1087
Targeting immune checkpoints: Releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer Journal. 2012 Review GET IT
Times cited: 50
Therapeutic implications of KIT in melanoma. Cancer Journal. 2012 Review GET IT
Times cited: 27
Chemotherapy in the Rwandan countryside: Universal issues a world away. Annals of Internal Medicine. 2012 Article GET IT
Times cited: 1
Beyond cancer vaccines: A reason for future optimism with immunomodulatory therapy. Cancer Journal. 2011 Review GET IT
Times cited: 24
The ice cream man. JAMA - Journal of the American Medical Association. 2011 Academic Article GET IT

VIVO Weill Cornell Medical College

Michael Postow Assistant Professor of Medicine

Publications

Selected publications

Background

Education and Training

Phone

Publications

Selected publications

Background

Education and Training